UnknownNCT05243329
Investigating the Therapeutic Effects of Psilocybin in Treatment-Resistant PTSD
Medication studyAges 18–70Canada
Understand this study
Who could participate?
Listed age limits: 18 years to 70 years.
- Listed locations
- WindsorSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: October 3, 2022
- Recruitment status
- Unknown
- Enrollment listed in the registry
- 20
- Sponsor
- Halucenex Life Sciences Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Canada
- Age range
- From 18 Years to 70 Years
- Official registry ID
- NCT05243329
- Official title
Show the full official title
Investigating the Therapeutic Effects of Psilocybin in Treatment-Resistant Post-Traumatic Stress Disorder
Recruitment & locations
Status unknownThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Windsor
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Halucenex Life Sciences Inc.
Does this study involve medication?
Yes. The study involves medication, including Psilocybin.
Who can participate?
Listed age limits: 18 years to 70 years.
